PURPOSE: The von Hippel-Lindau (vHL) phenotype is variable, which complicates genetic counseling and surveillance. We describe how the rate of new tumor development varies through the lifetimes of vHL patients and how it is influenced by age and genotype. METHODS: In a national cohort study, we included 52 VHL mutation carriers who were retrospectively followed for a total of 799 person-years. From birth to current age, 581 manifestations were diagnosed during 2,583 examinations in the study subjects. Manifestation rates were analyzed using Poisson regression and compared in groups of different ages, tumor sites, and genotypes. RESULTS: The rate of new tumor development varied significantly with age and was highest at 30-34 years (0.4 new tumors/year). Tumor location further influenced the rate. The risk of retinal tumors was highest in subjects during the teenage years but was highest for cerebellar tumors in subjects during their 30s. Truncating VHL mutation carriers had a significantly higher manifestation rate compared with missense mutation carriers (hazard ratio = 1.85, 95% confidence interval: 1.06-3.24, P value = 0.031). CONCLUSION: The rate of new manifestation development is not constant throughout the life span of vHL patients; instead, it varies significantly with age and genotype and depends on anatomical location. Retinal surveillance is crucial during the teenage years, whereas cerebellar surveillance is especially important in adulthood.Genet Med 18 1, 89-97.
PURPOSE: The von Hippel-Lindau (vHL) phenotype is variable, which complicates genetic counseling and surveillance. We describe how the rate of new tumor development varies through the lifetimes of vHL patients and how it is influenced by age and genotype. METHODS: In a national cohort study, we included 52 VHL mutation carriers who were retrospectively followed for a total of 799 person-years. From birth to current age, 581 manifestations were diagnosed during 2,583 examinations in the study subjects. Manifestation rates were analyzed using Poisson regression and compared in groups of different ages, tumor sites, and genotypes. RESULTS: The rate of new tumor development varied significantly with age and was highest at 30-34 years (0.4 new tumors/year). Tumor location further influenced the rate. The risk of retinal tumors was highest in subjects during the teenage years but was highest for cerebellar tumors in subjects during their 30s. Truncating VHL mutation carriers had a significantly higher manifestation rate compared with missense mutation carriers (hazard ratio = 1.85, 95% confidence interval: 1.06-3.24, P value = 0.031). CONCLUSION: The rate of new manifestation development is not constant throughout the life span of vHL patients; instead, it varies significantly with age and genotype and depends on anatomical location. Retinal surveillance is crucial during the teenage years, whereas cerebellar surveillance is especially important in adulthood.Genet Med 18 1, 89-97.
Authors: I R Maddock; A Moran; E R Maher; M D Teare; A Norman; S J Payne; R Whitehouse; C Dodd; M Lavin; N Hartley; M Super; D G Evans Journal: J Med Genet Date: 1996-02 Impact factor: 6.318
Authors: Sven Gläsker; Tae-Sung Sohn; Hiroaki Okamoto; Jie Li; Russell R Lonser; Edward H Oldfield; Alexander O Vortmeyer; Zhengping Zhuang Journal: Ann Neurol Date: 2006-01 Impact factor: 10.422
Authors: Russell R Lonser; John A Butman; Kristin Huntoon; Ashok R Asthagiri; Tianxia Wu; Kamran D Bakhtian; Emily Y Chew; Zhengping Zhuang; W Marston Linehan; Edward H Oldfield Journal: J Neurosurg Date: 2014-02-28 Impact factor: 5.115
Authors: Alisdair McNeill; Eleanor Rattenberry; Richard Barber; Pip Killick; Fiona MacDonald; Eamonn R Maher Journal: Am J Med Genet A Date: 2009-10 Impact factor: 2.802
Authors: E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton Journal: J Med Genet Date: 1991-07 Impact factor: 6.318
Authors: Alexander O Vortmeyer; Stephan Frank; Seon-Yong Jeong; Kristy Yuan; Barbara Ikejiri; Youn-Soo Lee; Deb Bhowmick; Russell R Lonser; Reginald Smith; Griffin Rodgers; Edward H Oldfield; Zhengping Zhuang Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Zhengping Zhuang; Jason M Frerich; Kristin Huntoon; Chunzhang Yang; Marsha J Merrill; Ziedulla Abdullaev; Svetlana D Pack; Sharon B Shively; Gordon Stamp; Russell R Lonser Journal: Sci Rep Date: 2014-02-17 Impact factor: 4.379
Authors: Anouk N A van der Horst-Schrivers; Wim J Sluiter; Roeliene C Kruizinga; Rachel S van Leeuwaarde; Rachel Giles; Maran J W Olderode-Berends; Thera P Links Journal: Fam Cancer Date: 2019-07 Impact factor: 2.375
Authors: Anass Hajjaj; Koen A van Overdam; Rogier A Oldenburg; Anna E Koopmans; Ans M W van den Ouweland; Annelies de Klein; Emine Kiliç Journal: Acta Ophthalmol Date: 2020-01-30 Impact factor: 3.761